Bluejay Diagnostics Completes Patient Enrollment In SYMON-II Multicenter Clinical Validation Study
Bluejay Diagnostics Inc BJDX
$0.86
▼ -7.46%
($-0.07)
🔥 High Short Interest
🎈 Low Float
📅 Earnings This Week
Open
$0.95
Prev Close
$0.93
Day Range
$0.86 – $0.95
52W Range
$0.83 – $16.68
Market Cap
$889,855
Beta
0.94
EPS (TTM)
$-53.96
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-11-10 |
| Shares Out. | 1,030,000 |
| Website | bluejaydx.com/ ↗ |
| Phone | 19786310152 |
| Employees | 6 |
| Net Income | -$1.9M |
| Free Cash Flow | -$6.7M |
| Total Assets | $5.6M |
| Total Liabilities | $1.4M |
| Equity | $4.2M |
About Bluejay Diagnostics Inc
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
Bluejay Diagnostics Inc is a publicly traded company under the ticker symbol BJDX on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2024-07-01)